We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study on Safety and Efficacy of MD05 in Comparison With Beta-TCP in Patients Undergoing Sinus Floor Augmentation

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2008 by Scil Technology GmbH.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00520377
First Posted: August 24, 2007
Last Update Posted: April 23, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
FGK Clinical Research GmbH
Information provided by:
Scil Technology GmbH
  Purpose
The primary objective is the area of newly formed bone (%) as assessed by histomorphometry with either MD05 or beta-TCP.

Condition Intervention Phase
Alveolar Ridge Augmentation Drug: MD05 Device: Beta-TCP and autologous bone Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study on Safety and Efficacy of MD05 in Comparison With Beta-TCP in Patients Undergoing Sinus Floor Augmentation

Further study details as provided by Scil Technology GmbH:

Primary Outcome Measures:
  • Area of newly formed mineralised bone tissue (%) as assessed by histomorphometry. [ Time Frame: Within 4 months after surgery ]

Secondary Outcome Measures:
  • evidence of uncompromised healing [ Time Frame: January 2008 ]

Enrollment: 31
Study Start Date: January 2005
Estimated Study Completion Date: May 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
MD05
Drug: MD05
recombinant human GDF-5 coated onto beta-tricalcium phosphate
Active Comparator: 2
Beta-TCP and autologous bone
Device: Beta-TCP and autologous bone
beta-tricalcium phosphate and autologous bone

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients requiring two-stage unilateral maxillary sinus floor augmentation (sinus lift) in case of insufficient bone height in the area of the posterior maxilla, prior to insertion of dental implants
  • Residual bone height at the site of planned implantation > 1 mm and < 5 mm
  • Male and female outpatients, 18 to 75 years old
  • Female patients must be infertile (either sterilized or postmenopausal). If a patient's menopausal status at screening is uncertain, levels of follicle stimulating hormone (FSH) should be determined. Patients with an FSH level > 25 IU/l and absence of menstrual bleeding > 6 months will satisfy the definition of postmenopausal status.
  • Patient has given informed consent.

Exclusion Criteria:

  • Women of childbearing potential, lactating women
  • Participation in another clinical study within 30 days prior to study start
  • Previous participation in this study
  • Last dental extraction (maxilla, posterior to canine) within the last 3 months
  • Failed sinus lift surgery and previous eradictive maxillary sinus surgery
  • Simultaneously bilateral sinus lift
  • Legal incompetence or restricted legal competence
  • Alcoholism, drug dependency, smoking
  • Acute or chronic infection at the application site, e.g., sinusitis
  • Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
  • Severe allergic rhinitis which requires permanent medication (Rosenlicht 1999)
  • Known intolerance of or hypersensitivity to beta-TCP or rhGDF﷓-5
  • Presence of local or systemic malignant disease or history of local or systemic malignant disease in the past 5 years
  • Patients requiring chemo- or radiotherapy
  • Previous or current radiotherapy of the head
  • Chronic liver disorder
  • Impaired renal function
  • Uncontrolled, insulin-dependent diabetes mellitus
  • Clinically relevant symptoms of thyroid dysfunction
  • Severe hypertension (RRdiast > 110 mmHg);
  • Clinically relevant cardiovascular disease
  • Systemic bone disease or illness having influence on bone metabolism,
  • Clinically relevant blood coagulation disorder,
  • Leukopenia < 3.500 leukocytes/µL
  • Previous or current treatment with systemic corticosteroids
  • Previous or current therapy with drugs having any influence on bone metabolism
  • Previous or current treatment with immunosuppressant medication
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00520377


Locations
Germany
Universitätsklinik Erlangen
Erlangen, Bayern, Germany, 91054
Praxis Dr. Gath
München, Bayern, Germany, 80336
IPI München GmbH
München, Bayern, Germany, 81925
Praxis Dr. Schmidinger
Seefeld, Bayern, Germany, 82229
Universitätsklinik Düsseldorf
Düsseldorf, Nordrhein Westfalen, Germany, 40225
Klinikum der Universität Mainz
Mainz, Rheinland Pflaz, Germany, 55131
Universitätsklinikum Schleswig Holstein
Kiel, Schleswig Holstein, Germany, 24105
Helios Klinik
Erfurt, Thüringen, Germany, 99089
Charité Universitätsmedizin Berlin
Berlin, Germany, 12203
Sponsors and Collaborators
Scil Technology GmbH
FGK Clinical Research GmbH
Investigators
Principal Investigator: Wilfried Wagner, Prof Dr Dr Universitätsklinikum Mainz
  More Information

Responsible Party: Björn Capsius, Scil Technology GmbH
ClinicalTrials.gov Identifier: NCT00520377     History of Changes
Other Study ID Numbers: Scil-MD05-C01
Sinus Lift Study
First Submitted: August 23, 2007
First Posted: August 24, 2007
Last Update Posted: April 23, 2008
Last Verified: April 2008

Keywords provided by Scil Technology GmbH:
Sinus Lift Surgery
Sinus Floor Augmentation
Insufficient Bone Height